Login to Your Account


Trizytek Comes Home

Alnara Licenses Altus Cast-off Trizytek from CF Foundation

By Trista Morrison


Wednesday, March 25, 2009
Alnara Pharmaceuticals Inc. is expected to announce Wednesday morning that it has licensed the Phase III cystic fibrosis drug Trizytek - which was dropped by Altus Pharmaceuticals Inc. in January - from the Cystic Fibrosis Foundation. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription


»

Our address has changed:
BioWorld | 115 Perimeter Center Place
Suite: 1100 | Atlanta, Georgia 30346, USA
 
For Sales Inquiries:
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
Fax: 1-770-810-3145
BioWorld.salessupport@thomsonreuters.com
 
Privacy Policy | Terms of Use
 
Part of Thomson Reuters
Note: our contact information has changed
Customer Service:
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
bioworld.support@thomsonreuters.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
© 2013 Thomson Reuters. Reproduction, reposting content is strictly prohibited.

Free Ezine

Sign up for Perspectives FREE e-mail newsletter

Click here